Mixed Results Announced for Trehalose in ALS Study
Topline data were announced from the phase 2/3 HEALEY ALS Platform trial evaluating SLS-005 for amyotrophic lateral sclerosis (ALS).
Source: neurologyadvisor.com
Full Analysis Set News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Full Analysis Set. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Full Analysis Set Today - Breaking & Trending Today
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rus
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy- Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferati...
Source: pharmiweb.com
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam...
Source: marketscreener.com
Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop Disruptive Bleeding
Addition of hemostatic patch complements Ethicon's comprehensive Biosurgery portfolio and ability to address critical unmet needs in controlling bleeding
Source: adnkronos.com
Celcuity Inc.: Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleMedian
Source: finanznachrichten.de